A missed dose, modelled: what happens to liraglutide concentrations over the following fortnight
Half-life, accumulation ratio and time to steady state are three separate quantities, and confusing them produces most of the bad advice in circulation.
Dosing
Page 26 of 31 of this archive, newest first.
What the new Canada guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The half-life question, answered properly
What the pharmacokinetic data supports about dose timing, missed doses and interruption.
A schedule that bends does not break
Nausea and gastric delay attenuate over weeks at an unchanged dose. That single physiological fact is the entire justification for holding.
Three weeks off is a fresh start, whether or not you want one
Supply interruption is the commonest cause of unplanned re-titration in this market, and it is almost never framed that way.
South Africa pharmacy body issues counselling standards for semaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Pancreatitis, obstruction, gallbladder: three things nausea can be
Pancreatitis is rare, was adjudicated in the outcome programmes, and did not show the imbalance early case reports suggested.
What the new New Zealand guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Reflux, early satiety, and the volume the stomach will accept
The clinical effect profile is almost fully predictable from where the receptor is expressed, which is unusual and useful.
Ireland pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
How a correct calculation becomes a wrong dose
We have catalogued what readers report, ranked by the size of the dosing error each produces.
Background rates, and why they matter for attribution
We give background rates alongside trial rates, because an event occurring during treatment is not thereby caused by it.
The United Kingdom pharmacy body issues counselling standards for dulaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Pancreatitis, obstruction, gallbladder: three things nausea can be
The features that should prompt urgent assessment, stated once and plainly.
A schedule that bends does not break
Reducing a dose is not going backwards. In a tolerability-limited class it is the mechanism by which the ceiling is found.
Nigeria pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
What the trials adjudicated, and how
We give background rates alongside trial rates, because an event occurring during treatment is not thereby caused by it.
What the anaesthetists said, and then said again
The evidence is real, modest, and mostly retrospective. The guidance is correspondingly cautious and has been revised toward individualisation.
One receptor, several signals: the case for reading retatrutide as a biased agonist
What the in-vitro data supports, what it does not, and where the extrapolation to a person begins.
Escalating past the approved maximum, examined honestly
Where the curve flattens, what flattens with it, and what does not.